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A B S T R A C TObjective: To pilot the use of multicriteria decision analysis to estab-
lish and apply a framework of weighted attributes to value orphan
medicinal products. Methods: Literature searches on the natural his-
tory and burden of 40 rare diseases and of how payers assess treatment
value and three workshops with, respectively, GlaxoSmithKline man-
agers working on orphan medicinal products, European Union clinical
and health economics experts, and representatives of rare diseases
patient groups in the European Union. Results: Eight nonmonetary
attributes were identiﬁed and weights agreed: four concern the disease
being treated and four the treatment itself. About half of the weightsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.10.002
ohe.org.
ondence to: Jon Sussex, Ofﬁce of Health Economicswent to attributes of the disease treated and half to attributes of the
treatment. Patient group representatives gave greater weight than did
the experts to patients’ and carers’ quality of daily life. Conclusions:
The multicriteria decision analysis approach piloted works and could
be developed for use by payers and health technology assessment
bodies.
Keywords: HTA bodies, methods, orphan drugs, payers, rare diseases.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
This article presents an experimental pilot study that tests a
multicriteria decision analysis (MCDA) approach [1] to establish a
framework for valuing orphan medicinal products (OMPs) and
providing an explicit understanding of trade-offs for decisions on
their eligibility for funding.
All health care systems’ health technology assessment (HTA)
and reimbursement decisions depend on an implicit, if not
explicit, assessment of value as the ﬁrst step. Efforts by policy-
makers and payers to better determine the value of medicines are
widespread internationally. The 2011 AMNOG (Arzneimittel-
marktneuordnungsgesetz, or medicines market restructuring
law) reforms in Germany and the development of “value-based
pricing” in the United Kingdom are two high-proﬁle examples
[2,3] among many others [4,5]. No HTA agency yet uses MCDA,
but the European Medicines Agency is developing an MCDA
approach to balancing the beneﬁts and risks of new medicines
considered for licensing [6] and National Health Service England
has proposed what is in effect an MCDA process for deciding
which oncology medicines will be funded by the national Cancer
Drugs Fund for National Health Service patients in England [7].
The literature on MCDA in health care is growing [1,8].
MCDA is a set of methods to aid decision making where more
than one criterion is relevant, which make explicit the impact onthe decision of all the criteria and the relative importance attached
to them. The main steps are (see [1] for more detail) as follows:oc
, 7testablish the decision context—what is to be decided, by whom;
 identify attributes for assessing the value of each medicine;
 assign weights to the attributes to indicate their relative
importance to the decision;
 score the expected performance of each medicine against the
attributes;
 combine weights and scores to indicate overall value; and
 consider the implications of the results and test their sensi-
tivity to reasonable variations in weights and scores.
Variants of MCDA range from those using sophisticated algo-
rithms to identify the total (dis-)beneﬁts of an option to more basic
approaches limited to providing and recording a structured and
explicit deliberative process. All forms of MCDA aim to achieve
replicability and transparency, and hence accountability, in deci-
sion making. MCDA has been extensively used in health care and
other sectors (transport, social services, immigration policy, etc.).
MCDA aids and structures the exercise of judgment by decision
makers but does not do away with the need for that judgment [8].
OMPs are treatments for patients with rare diseases, deﬁned
in Europe as conditions affecting fewer than 1 in 2000 people.
Rare diseases are often chronic, progressive, and life threatening;iety for Pharmacoeconomics and Outcomes Research (ISPOR).
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treatments for these diseases. Small populations, substantial
heterogeneity, lack of knowledge about natural history, and
difﬁculty in deﬁning practical clinical end points create greater
uncertainty around evidence in rare diseases than in common
ones. The development of OMPs is often accompanied by partial
knowledge of diseases and scarce medical expertise. Legislation
has accordingly been introduced in the United States and the
European Union (EU), establishing special incentives for the
development of treatments for rare diseases, and increased
numbers of orphan drug designations have followed [4].
Payers commonly treat OMPs distinctly from other medicines. A
number of HTA systems have special arrangements for the assess-
ment or reimbursement of OMPs. In England and Wales, treat-
ments for very rare conditions are assessed and commissioned in a
separate process from other treatments (until April 2013 by the
Advisory Group for National Specialised Services [9] and since then
by the National Institute for Health and Care Excellence [NICE]
whose Highly Specialised Technologies Evaluation Committee is
building on the work done by the Advisory Group for National
Specialised Services [10]). The process uses criteria in addition to
health gains, including attributes related to societal value and
impact on clinical practice. In Scotland, a special fund speciﬁcally
for OMPs was set up in early 2013 [11]. At the European level, policy
initiatives are aimed at improving the approach to assessing the
value of new OMPs. For example, the EUCERD (European Union
Committee of Experts on Rare Diseases) [12] is developing proc-
esses to inform decision makers about the clinical added value of
OMPs and facilitate timely reimbursement.
Winquist et al. [13] have proposed a process for reviewing
OMPs by payers that works around problems with demonstrating
clinical effectiveness. But we have not been able to ﬁnd in the
literature a value framework for assessing OMPs that sets clinical
effectiveness alongside other attributes of value.
Launching a treatment for a hitherto untreated rare disease
puts that disease on the clinical map. Clinicians are then more
likely to be aware of the disease, to recognize cases that present to
them, and to have the necessary skills to help [14]. This suggests
that the existence of an unmet need for treatment might be more
important when determining the value of an OMP than when
evaluating treatments of more prevalent conditions.
For all these reasons, it is important to relate the “signiﬁcant
beneﬁt” value criterion required for OMP designation with a
framework that, as pointed out by Hughes-Wilson et al. [15],
would permit consistent value assessments of OMPs across
different jurisdictions and across diverse rare diseases. To that
end, we piloted the identiﬁcation of beneﬁt attributes to include
in an OMP value framework and the determination of their
relative importance via an MCDA process.
We did not attempt to assign monetary values to different
levels of the beneﬁt attributes. Few HTA or pricing and reim-
bursement (P&R) bodies do so explicitly, and NICE offers only a
range of values and only for one dimension of value, namely, the
incremental quality-adjusted life-years (QALYs) produced [16].
We focus on the beneﬁts of OMPs, which can then be compared
with net costs, including the price of the OMP itself.Methods
We identiﬁed an initial list of value attributes from a literature
review of rare diseases, a review of HTA for OMPs, and interviews
with clinical experts, economists, and representatives from rare
disease patient groups. A literature search was undertaken on the
natural history and burden of 40 rare diseases (see Appendix A in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2013.10.002. There are more than 7000 rare diseases, and so acomprehensive literature review was impractical. A subset of 40
diseases was selected on the basis of availability of literature on
morbidity, mortality, broader patient and carer burden, disease
frequency, severity, degree of scientiﬁc understanding, and prog
ress in developing effective treatments. Searches were conducted
in MEDLINE, EMBASE, the Cochrane database, Orphanet, and the
EURORDIS patient association Web site. For each condition,
disease impact was broken down by individual or group affected
(patients, family, society), nature of the effect (pathological,
clinical, symptomatic, outcomes, economic), and the proximity
of the effect to the primary manifestation of the disease.
A second search looked for how existing payer frameworks
estimate treatment value in 10 OECD (Organisation for Economic
Co-operation and Development) countries with OMP regulatory
pathways and well-established pharmaceutical reimbursement
processes (Australia, France, Germany, Italy, Japan, The Nether-
lands, Spain, Sweden, the United Kingdom, and the United States).
A related search focused on rationales given in reimbursement
decisions for OMPs in those EU countries where the reports were
available in English: the United Kingdom (NICE and SMC [the
Scottish Medicines Consortium]), France (Transparency Commis-
sion), and Germany (GBA [Gemeinsame Bundesausschuss, or the
Joint Federal Committee]—IQWiG [Institut für Qualität und Wirt-
schaftlichkeit im Gesundheitswesen, or the Institute for Quality
and Efﬁciency in the Health Service]). These searches were sup-
plemented through 10 interviews with clinical experts, academics
specialized in health economics and policy, and rare diseases
patient group representatives in the EU and the United States.
This process yielded 14 attributes. Practical guides to MCDA
recommend using fewer than 10 attributes. We excluded the net
monetary cost impacts of the disease and the treatment, as to
include them would require monetary values for all the non-
monetary attributes. We sought instead to establish the value of
an OMP to set against its net cost impact. We discussed the
attributes at a workshop in March 2012 with GSK managers
working on the development and commercialization of OMPs,
and aggregated them into the following eight attributes: impact of the rare disease and associated unmet need:
1. availability of effective treatment options/best supportive
care in the absence of the new medicine;
2. disease survival prognosis with current standard of care;
3. disease morbidity and patient clinical disability with cur-
rent standard of care;
4. social Impact of the disease on patients’ and carers’ daily
lives with current standard of care;impact of the new medicine:
5. treatment innovation, deﬁned as the scientiﬁc advance of the
new treatment together with contribution to patient outcome;
6. evidence of treatment clinical efﬁcacy and patient clinical
outcome;
7. treatment safety; and
8. social impact of the treatment on patients’ and carers’
daily lives.The rationales for these attributes and their particular relevance in
rare diseases, with references to the literature from which they are
drawn, are detailed in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2013.10.002. The inclusion of attributes of the
disease, as well as of the treatment itself, is recognized as relevant
by various authorities (e.g., [3] and [17]).
To provide a combined value assessment based on these
attributes, we used an MCDA approach. We selected a “value
measurement model” [8] as being of most value to HTA and
Table 1 – Proﬁles of the two OMPs rated in the MCDA
workshops.
Value attribute Treatment A Treatment B
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attributes and using them to rate example OMPs were ﬁrst piloted
in the March 2012 workshop with GSK managers and then formed
the basis of two further workshops:Availability of Yes No
effective existingwith clinical and health economics experts from France, Ger-
many, Italy, Spain, and the United Kingdom in April 2012; andtreatment options
Main target patient
outcome
Survival Progression of
disease
Therapeutic area Immunodeﬁciency Neuromuscular
Prevalent population
range in the
European Union
250–600 patients 3000–8000
patients
Pivotal trial—data
package
Open clinical trial
(no control group)
Randomized
double-blind
placebo
controlled
MCDA, multicriteria decision analysis; OMPs, orphan medicinal
products.with representatives of rare diseases patient groups in the EU
in August 2012.
Each of these 1-day workshops included 6 to 11 participants plus the
authors of this article as facilitators. In addition, medical/scientiﬁc
specialists were on hand to provide factual information and clariﬁ-
cation about the OMPs assessed. The workshops were highly struc-
tured and included participants working in small subgroups (three to
four per subgroup) to complete tasks within strict time limits.
Following an introduction explaining the purpose and nature of
the workshop, the ﬁrst substantive session in each workshop was
devoted to validating the set of value attributes. Participants at the
April and August workshops were offered the opportunity to
change the list of attributes agreed at the March workshop if they
had concerns, but they were content with the eight attributes.
We took a societal perspective when establishing the value
attributes, while recognizing that payers and HTA bodies in some
countries currently take narrower perspectives limited to clinical
effectiveness or health gain [18]. We asked workshop participants
when determining attributes’ relative weights to take into account
the interests of all relevant stakeholders including patients, their
families and carers, payers, and the national economy.
In the second session of each workshop, the participants
assigned relative weights to the attributes. Participants were divided
into groups of three to four plus a facilitator. Before breaking into
the groups, participants were asked to consider by themselves all
the attributes and to allocate each of them initially to one of three
headings (“high,” “medium,” or “low” importance) for determining
the value of an OMP. Participants then discussed in their small
groups how to allocate 100 weighting points across the eight
attributes. Each group reached a consensus weight out of 100 for
each criterion. The individual groups’ weightings were then
reported to a plenary session, any signiﬁcant differences between
groups’ weightings were discussed, and each group was given the
opportunity to revise its weightings. It always proved possible in the
plenary discussion to reach a consensus weighting for each attrib-
ute: all participants were content to accept an average of the groups’
individual weightings, as amended following the plenary discus-
sion, where there remained any difference in those weightings.
An important part of the study was to test the views of rare
disease patient groups, clinical experts, and health economists
about the balance of weights between the two groups of attrib-
utes: those related to the disease being treated and those
concerning the effectiveness of the new medicine. Empirical
studies support the use of the severity of the disease being
tackled as a criterion for determining the value of a treatment
although the exact strength of that support is less clear [19].
There is less evidence about the importance of unmet need per se
although what there is does suggest that it is relevant [20].
After establishing the attributes’ weights, the workshop par-
ticipants rated two case study OMPs from the GSK pipeline for
their achievement of the eight attributes. We selected OMPs with
clearly differentiated proﬁles, described in Table 1. Participants
were provided before the workshop with concise briefs, in non-
technical language, describing the nature of the disease in each
case and its impact on patients and carers, and the evidence
about the characteristics and impacts of treatment with the
medicine, based on available clinical data.
Participants were given time to rate by themselves each new
treatment against each attribute, before going into the samesmall discussion groups as before. The rating scale ranged from 1
(worst score) to 7 (best score), as per the deﬁnitions provided in
Appendix C in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2013.10.002. Participants were required to allocate
only whole number scores, not fractions or decimal places. The
1 to 7 scale was chosen to permit sufﬁcient discrimination
without introducing an inappropriate impression of precision.
Scripts describing the rating scale for each of the eight attributes
(available from the authors on request) were provided to work
shop participants. Within the small groups, the rating of each
treatment, in turn, was discussed for each attribute. A commen-
surate process to that for the weighting task was followed, with
consensus scores for each case study OMP against each of the
attributes being agreed in a plenary discussion.
In the ﬁnal workshop session, participants compared the
overall value scores of the two OMPs (given by the weighted
sum of the scores per attribute) and the key attributes driving
that score in each case. Aided by an expository Excel-based tool
developed for the project, sensitivity analyses were conducted in
front of the workshop participants, on the basis of combinations
of adjustments to relative weightings of criteria and to scorings
against each criterion, within the ranges of weights and values
that had been discussed in the earlier plenary sessions.Results
We report the outcomes of the two workshops with participants
invited by, but external to, GSK, namely, a group of European
clinical and health economics experts at the April workshop and
a group of European rare disease patient group representatives at
the August workshop. The results are presented as a “proof of
concept” rather than as deﬁnitive values.
Both workshops proved successful as pilots of the MCDA
process. All participants proved able and willing to engage with
the tasks in all sessions of the workshop, and a consensus was
agreed with respect to attribute weightings and to the scoring of
medicines against those attributes.
Table 2 summarizes the attribute weights from the “Experts” and
“Patients” workshops, respectively. The clinical experts and health
economists considered that the most important attribute was
evidence of impact on patient outcomes, with 28% of the total
weighting. The next most important criterion was the extent to
which there is currently an alternative treatment, with a 19%
weighting. The clinical and health economics experts accorded no
Table 2 – Attribute weights (%) from two workshops.
Attribute weights (%) Experts
workshop
Patients
workshop
Availability of existing treatments 19.5 11
Disease survival prognosis with
current soc
14 11.5
Disease morbidity and patient
clinical disability with current
soc
12 15
Social impact of disease on
patients’ and carers’ daily lives
with current soc
8 15
Subtotal weight for impact of
disease/extent of unmet need
53.5 52.5
Treatment innovation: scientiﬁc
advance þ contribution to
patient outcome
0 5
Evidence of treatment clinical
efﬁcacy and patient clinical
outcome
27.5 17.5
Treatment safety 8 7.5
Social impact of treatment on
patients’ and carers’ daily lives
11 17.5
Subtotal weight for impact of new
medicine
46.5 47.5
Total 100 100
soc, current standard of care.
Table 3 – Ratings of the OMPs from experts workshop.
Attribute Weight
Rating
Availability of existing treatments 19.5 5
Disease survival prognosis 14 6
Disease morbidity/clinical disability 12 6
Disease social impact on daily lives 8 7
Treatment innovation 0 7
Treatment clinical efﬁcacy/outcome 27.5 6
Treatment safety 8 5
Treatment social impact on daily lives 11 6
Total 100
OMPs, orphan medicinal products.
Table 4 – Ratings of the OMPs from patients workshop.
Attribute Weight
Rating
Availability of existing treatments 11 6
Disease survival prognosis 11.5 7
Disease morbidity/clinical disability 15 7
Disease social impact on daily lives 15 6
Treatment innovation 5 6
Treatment clinical efﬁcacy/outcome 17.5 6
Treatment safety 7.5 7
Treatment social impact on daily lives 17.5 6
Total 100
OMPs, orphan medicinal products.
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advance, with the stated rationale that when the other seven
attributes are taken into account, this attribute would not be seen
by patients, carers, or health care payers as adding any further value.
The rare disease patient group representatives differed from
the clinical and health economic experts in some aspects of the
weightings (Table 2). The patient group representatives spread
the weights more equally across the eight value attributes. They
gave more weight than did the clinicians/economists to the
impacts of the disease, and of the new treatment, on individual
patients’ and carers’ daily lives and were also willing to give some
weight (5%) to treatment innovation/scientiﬁc advance. The (un-)
availability of existing treatments was less important to the
patient representatives than it was to the clinicians/economists.
So too was evidence of treatment clinical efﬁcacy and patient
clinical outcome, although this remained the (equal) most
important criterion, as it had been for the clinicians/economists.
Overall, both sets of workshop participants agreed, independ-
ently, to give slightly more weight to the attributes of the disease
being targeted than to the impacts of the new medicine aimed at
it: around 53% versus 47%. This result was discussed in the
plenary session at each workshop and each time was conﬁrmed
as the collectively desired balance.
How the two case study treatments were rated against each of
the eight beneﬁts attributes at ﬁrst the experts workshop and
later the patient groups workshop is shown in Tables 3 and 4,
respectively. At each workshop, the participants found it easy to
agree after discussion a consensus rating for each attribute and
treatment. The clinical and health economics experts rated
Treatment A highly: a total weighted score of 580.5 (within aTreatment A Treatment B
Weighted score Rating Weighted score
97.5 7 136.5
84 6 84
72 7 84
56 6 48
0 6 0
165 4 110
40 4 32
66 4 44
580.5 538.5
Treatment A Treatment B
Weighted score Rating Weighted score
66 6 66
80.5 5 57.5
105 7 105
90 6 90
30 6 30
105 5 87.5
52.5 5 37.5
105 5 87.5
634 561
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rated Treatment B somewhat lower overall: a total weighted
score of 538.5. The minimum individual rating they gave for any
attribute for either treatment was a “4” for Treatment B for three
of the treatment attributes, and the highest individual rating they
gave was “7” (out of 7) for two of the disease characteristics of
Treatment B and for one disease characteristic and one treatment
characteristic of Treatment A (Table 3).
Table 4 shows that the patient group representatives, using
their weights for the attributes and their assessment of the scores
for the case study treatments against those attributes, rated both
treatments more highly than did clinical and health economics
experts, but like the experts they rated Treatment A above
Treatment B. Their reasons for rating Treatment A above Treat-
ment B overall were broadly the same as the experts’: better
treatment outcomes achieved by Treatment A. Where the two
sets of workshop participants differed from one another most
was in their ratings of the diseases being treated. The experts
considered disease B to be untreated currently (rating ¼ 7 for
“availability of existing treatments”) but that the current stand-
ard of care for disease A did provide a little relief for patients
(rating ¼ 5). The patient group representatives considered both
diseases to be equally poorly treated currently (rating ¼ 6 for
both). Conversely, the experts saw the survival prognosis as
equally poor for disease A and disease B (both rated at 6), whereas
the patient group representatives saw the prognosis as being
rather worse for sufferers from disease A (rating ¼ 7) than for
sufferers from disease B (rating ¼ 5).
The process summarized in Tables 3 and 4 made explicit the
trade-offs made between different value attributes in reaching
the overall assessment of value for each OMP. For each attribute,
workshop participants were able to discriminate between factors
they thought did or did not impact value of treatment. Sensitivity
analysis showed that only with implausibly large changes to
attributes’ weights would the ranking of the two case study
medicines by either workshop change. For example, using the
patient groups’ attribute weights and experts’ ratings, the overall
weighted scores for Treatment A and Treatment B would become
601.5 and 541, respectively. Using experts’ weightings and patient
groups’ ratings would give overall scores of 634 and 551.5,
respectively, for Treatment A and Treatment B.Discussion
We discuss the following: how our ﬁndings compare with other literature on MCDA in
HTA; the appropriateness of our MCDA approach compared with
alternatives; the practicality of an MCDA-based approach to aid real-world
decision making by payers and the HTA bodies that
advise them; and future work to build on the pilot study.
The principal motivation for our pilot study is the absence from
the literature of explicit, weighted, value frameworks for OMPs.
Most use of MCDA in health care has been by health care payers
attempting to prioritize options at a relatively high level; a
concise survey of such MCDA studies is given in Devlin and
Sussex [1]. We are not aware that any HTA or P&R body currently
states that it applies MCDA methods. However, some HTA bodies
measure health gain as QALYs, and we note that the process of
determining the dimensions of health state that are included
(e.g., in the EuroQol ﬁve-dimensional questionnaire or other
instrument) and then of weighting those health states relativeto one another via value sets is itself an MCDA process. It is but
one logical step further to consider a set of attributes beyond
QALYs alone, and derivation of weights for those attributes, for
use in HTA. We have focused on OMPs, noting that HTA and
payer bodies often assess them via processes that are distinct
from those for other medicines because of the special issues
OMPs raise (see the Introduction).
One of the most striking ﬁndings from our pilot study was the
large weight given to the nature of the disease being treated, as
distinct from the result of using the medicine to treat it. There is a
growing literature on the role of disease severity and of the hitherto
unmet need in valuing health care interventions [19,20], which is
consistent with our ﬁnding, which was common both to the patient
group representatives and to the clinical/economics experts.
Our pilot found that the patient group representatives gave
greater weight than did the clinical/economics experts to attributes
concerned with the quality of the day-to-day lives of patients and
their carers. This makes intuitive sense—the patient group repre-
sentatives are more aware of the practical implications of living
with rare conditions—but we are not aware of other studies
comparing the attribute weights of patient groups versus clinical/
technical experts and so do not know whether this kind of differ-
ence extends to less rare conditions or other MCDA processes.
Identiﬁcation of the best form of MCDA for payers and their
HTA bodies to value OMPs remains an empirical question. There
is a continuum of approaches ranging from algorithmic methods
to more deliberative processes that allow for exceptions to be
made [1]. Among the more algorithmic approaches there are
various ways of identifying attributes and their weights and of
comparing options, for which there is no space to go into in this
short article (the interested reader is recommended to refer to [1]
and [8] for detailed but accessible discussions). Each approach
has advantages and disadvantages. Decision makers may be
reluctant to submit themselves to public scrutiny, but secrecy
damages public conﬁdence in their decisions. MCDA approaches
increase the defensibility of decisions. Therefore, on balance we
believe that a way forward is where an MCDA tool is used to help
decision-makers’ deliberative processes rather than being applied
in a mechanistic way.
We identiﬁed value attributes via an extensive literature
search and a deliberative process at a workshop. Weights were
not available from the literature; they were determined via a
deliberative process as an integral part of the MCDA itself.
Because this was a pilot study, it was important to have the
opportunity to discuss in detail with experts and rare disease
patient group representatives both the attributes and how they
were weighted. This implied a workshop approach rather than a
discrete choice experiment (DCE) or use of “remote” tools such as
“1000Minds” [1].
We use a “value measurement model” to assess an OMP
against the current standard of care and to permit comparison
of the value of different OMPs treating different rare conditions.
This has the advantage of being easier to use and present to
nontechnical audiences, relative to “outranking” and “goal pro-
gramming” approaches (see [8]).
The way we conducted our pilot could be replicated in real-
world settings by the decision-making groups with HTA and
reimbursement bodies, for example, the Appraisal Committees
and Citizens Council employed by NICE in the United Kingdom.
Any MCDA process based on workshops of limited scale and
duration may be criticized for superﬁciality, but HTA and P&R
committees suffer equally in this regard. Pragmatism dictates the
time and resourcing in all cases. None of the participants in our
1-day workshops, several of whom have worked on or advised
HTA bodies and their committees, expressed an unwillingness to
agree and weight value attributes, and then rate treatments
against those attributes.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 6 3 – 1 1 6 91168Weighting attributes and rating how well an OMP achieves
each attribute are not particularly difﬁcult tasks for an individual
to perform. Potentially more difﬁcult is to ensure that when a
number of people’s views are sought, everyone’s understanding of
the evidence on a disease and how well a medicine treats it is the
same and likewise their understanding of the reason for assessing
the value of the medicine. The workshops proved to be an effective
way of achieving shared understanding of beneﬁt attributes and
buy-in to a collective weighting of them. A similar process would
be practical for the appraisal committee of an HTA body.
In countries where there are already separate processes for
OMPs, our MCDA tool is evidently capable of being applied by the
kinds of clinical and economic experts, and patient representa-
tives, who already sit on and advise (or would like to) HTA bodies.
The main barrier appears to be reluctance by HTA bodies and/or
payers to be that transparent. But transparency is essential if
clear and consistent signals are to be sent to investors in
medicines research so that resources are prioritized to those
avenues of R&D most likely to produce the OMPs most valued by
the people whom health care payers and their agencies exist to
serve. A practical and important step in the direction of trans-
parency could be to use MCDA approaches within the deliberative
processes of HTA bodies for all their decisions, combined with
publication alongside each decision of all the attributes considered
and to what extent they did or did not affect the ﬁnal decision.
To achieve that will require HTA bodies to try MCDA
approaches for themselves. This is not a costly undertaking,
and it would be reversible if insurmountable obstacles were
deemed to have arisen. If a “testing by doing” approach were
adopted, value sets and weights would be established de facto and
could be reﬁned as MCDA approaches are used repeatedly over
time and across decisions. In the long term, it might become
possible to conduct a multinational, for example, pan-European,
assessment of the value of OMPs (which would leave reimburse-
ment as a country-level decision), in the spirit of the ongoing
initiatives in the European policy arena [12].
Development for use in real-world decision-making settings of
the value framework we identiﬁed could involve further validation
of those attributes, for example, by running multiple focus groups
involving a broader range of participants with different health
status, sociodemographic characteristics, and nationality. How-
ever, we reviewed a large amount of material to generate the list
of attributes, and we therefore consider it unlikely that the result of
such validation would differ much from the list proposed here.
Our pilot study revealed differences between experts’ and
patient group representatives’ views of the relative importance of
some attributes. It would be necessary to repeat the study with
larger samples of experts and patient group representatives to
test the robustness of these differences. But the patient group
representatives in our workshops represented a diverse range of
rare diseases and all had experience at national and/or suprana-
tional levels of informing rare diseases policy. The clinical and
health economics experts all had practical experience of inform-
ing payers and policymakers at national and/or supranational
levels about rare disease value assessment. So, there is reason to
believe that the different weights we found might persist even
with the involvement of larger numbers of experts and patient
group representatives.
Further research would be useful to determine the extent to
which different groups’ ratings of a treatment against a particular
beneﬁt attribute were due to different understanding of the
evidence about that attribute. Further workshops, or a DCE, could
provide valuable insights by comparing the results from groups
provided with different degrees of information and education
about the rare diseases and OMPs to treat them.
To produce a single consensus set of weights within a
jurisdiction would be a necessary step for implementation andhence deriving such a set of weights from a larger and fully
representative sample of stakeholders is needed for each juris-
diction. We experienced great willingness by all participants
within each of the workshops to listen to others’ views and
arguments, to compromise, and to agree. We feel conﬁdent that
adding a further stage to the process where, for example, the
results from the two sets of participants were brought to a
combined plenary meeting of all participants would be likely to
yield a mutually acceptable set of weights.
It will also be important to elicit attributes’ weights from the
general public (the ultimate funders of health care via taxation,
social insurance, or private insurance) and alternativemethodologies
such as DCEs could be used for that purpose. There is a growing body
of research using DCEs in this and other ways in health technology
evaluations [21]. Estimating attributes’ weights across different
countries will reveal how far preferences over treatment character-
istics vary between health care payers and systems.
The aim of our study was to provide a framework to measure
and value the beneﬁts of OMPs. Decision-making processes
involve a further step, which is beyond the scope of this short
note, namely, the comparison of beneﬁts with net costs to
determine price, reimbursement status, and/or recommended
use within a health care system.Conclusions
Given the intrinsically complex nature of the rare diseases and
OMPs environment, an MCDA approach for rare disease treat-
ment value assessment has the merit of ensuring shared under-
standing of the elements of value as well as a clear articulation of
trade-offs between those elements. We successfully piloted such
an approach with patient group representatives and clinical and
health economics experts who advise HTA bodies and payers.
The MCDA approach offers a possible construct for more com-
prehensive guidance to HTA and P&R decision making.
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